keyword
https://read.qxmd.com/read/38546982/what-are-the-impacts-of-introducing-an-sglt2-inhibitor-after-a-recent-episode-of-acute-kidney-injury
#1
JOURNAL ARTICLE
Thyago Proença de Moraes
No abstract text is available yet for this article.
March 1, 2024: Kidney360
https://read.qxmd.com/read/38543148/sodium-glucose-cotransporter-2-inhibitors-in-non-diabetic-kidney-disease-evidence-in-experimental-models
#2
REVIEW
Giovanna Castoldi, Raffaella Carletti, Francesca Barzaghi, Michela Meani, Giovanni Zatti, Gianluca Perseghin, Cira R T Di Gioia, Gianpaolo Zerbini
Sodium glucose cotransporter 2 (SGLT2) inhibitors are a class of glucose-lowering agents widely used for the treatment of type 2 diabetes mellitus. A number of clinical trials in type 2 diabetic patients with different degrees of renal impairment have clearly demonstrated that SGLT2 inhibitors reduce the progression rate of diabetic kidney disease. Furthermore, recent studies have shown that SGLT2 inhibitors also exert a protective effect in the case of non-diabetic kidney disease. Consequently, it has been hypothesized that the nephroprotective activity of these drugs could exceed the canonical impact on glycemic control and that the resulting beneficial effects could be the consequence of their pleiotropic properties (proven reduction of inflammation, fibrosis, oxidative stress and sympathetic nervous activity) both at systemic and tissue levels, suggesting that the efficacy of these drugs could also be extended to non-diabetic nephropathies...
March 11, 2024: Pharmaceuticals
https://read.qxmd.com/read/38542088/beyond-quadruple-therapy-and-current-therapeutic-strategies-in-heart-failure-with-reduced-ejection-fraction-medical-therapies-with-potential-to-become-part-of-the-therapeutic-armamentarium
#3
REVIEW
Christos Kourek, Alexandros Briasoulis, Adamantia Papamichail, Andrew Xanthopoulos, Elias Tsougos, Dimitrios Farmakis, Ioannis Paraskevaidis
Heart failure with reduced ejection fraction (HFrEF) is a complex clinical syndrome with significant morbidity and mortality and seems to be responsible for approximately 50% of heart failure cases and hospitalizations worldwide. First-line treatments of patients with HFrEF, according to the ESC and AHA guidelines, include β-blockers, angiotensin receptor/neprilysin inhibitors, sodium-glucose cotransporter 2 inhibitors, and mineralocorticoid receptor antagonists. This quadruple therapy should be initiated during hospital stay and uptitrated to maximum doses within 6 weeks after discharge according to large multicenter controlled trials...
March 7, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38542060/recent-advances-in-the-management-of-diabetic-kidney-disease-slowing-progression
#4
REVIEW
Na Wang, Chun Zhang
Diabetic kidney disease (DKD) is a major cause of chronic kidney disease (CKD), and it heightens the risk of cardiovascular incidents. The pathogenesis of DKD is thought to involve hemodynamic, inflammatory, and metabolic factors that converge on the fibrotic pathway. Genetic predisposition and unhealthy lifestyle practices both play a significant role in the development and progression of DKD. In spite of the recent emergence of angiotensin receptors blockers (ARBs)/angiotensin converting enzyme inhibitor (ACEI), sodium-glucose cotransporter 2 (SGLT2) inhibitors, and nonsteroidal mineralocorticoid receptors antagonists (NS-MRAs), current therapies still fail to effectively arrest the progression of DKD...
March 7, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38541972/risk-of-diabetic-ketoacidosis-associated-with-sodium-glucose-cotransporter-2-inhibitors-a-network-meta-analysis-and-meta-regression
#5
REVIEW
Kannan Sridharan, Gowri Sivaramakrishnan
Background: Sodium glucose cotransporter-2 inhibitors (SGLT2is) represent an emerging class of drugs with diverse indications. Despite their therapeutic potential, concerns regarding safety, particularly diabetic ketoacidosis (DKA), remain contentious, with uncertainty regarding differences among various SGLT2is. This study aimed to conduct a network meta-analysis and meta-regression to evaluate the risk of SGLT2i-induced DKA and associated factors. Methods: We systematically searched electronic databases for randomized clinical trials assessing SGLT2is across indications, reporting incidences of DKA...
March 18, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38541843/the-reasons-for-the-low-uptake-of-new-antidiabetic-drugs-with-cardiovascular-effects-a-family-doctor-perspective
#6
REVIEW
Tomislav Kurevija, Dunja Šojat, Zvonimir Bosnić, Blerim Mujaj, Silvija Canecki Varžić, Ljiljana Majnarić Trtica
Chronic diseases, such as type 2 diabetes (T2D), are difficult to manage because they demand continuous therapeutic review and monitoring. Beyond achieving the target HbA1c, new guidelines for the therapy of T2D have been introduced with the new groups of antidiabetics, glucagon-like peptide-1 receptor agonists (GLP-1ra) and sodium-glucose cotransporter-2 inhibitors (SGLT2-in). Despite new guidelines, clinical inertia, which can be caused by physicians, patients or the healthcare system, results in T2D not being effectively managed...
March 12, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38540270/transforming-diabetes-care-the-molecular-pathways-through-which-glp1-ras-impact-the-kidneys-in-diabetic-kidney-disease
#7
REVIEW
Merita Rroji, Goce Spasovski
Diabetic kidney disease (DKD) is a substantial complication of type 2 diabetes (T2D), presenting challenges in chronic kidney disease (CKD) management. In addition to traditional and recent therapies, including angiotensin, converting enzyme (ACE) inhibitors, angiotensin receptor blockers, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists, the evolution of antihyperglycemic treatments has introduced a promising agent, glucagon-like peptide-1 receptor agonist (GLP-1RA) for the management of DKD...
March 14, 2024: Biomedicines
https://read.qxmd.com/read/38540200/proteomic-profiling-of-sglt-2-inhibitor-canagliflozin-in-a-swine-model-of-chronic-myocardial-ischemia
#8
JOURNAL ARTICLE
Dwight D Harris, Sharif A Sabe, Mark Broadwin, Christopher Stone, Cynthia Xu, Jiayu Hu, Meghamsh Kanuparthy, M Ruhul Abid, Frank W Sellke
BACKGROUND: Sodium-glucose cotransporter-2 (SGLT2) inhibitors are known to be cardioprotective independent of glucose control, but the mechanisms of these benefits are unclear. We previously demonstrated improved cardiac function and decreased fibrosis in a swine model of chronic myocardial ischemia. The goal of this study is to use high-sensitivity proteomic analyses to characterize specific molecular pathways affected by SGLT-2 inhibitor canagliflozin (CAN) therapy in a swine model of chronic myocardial ischemia...
March 6, 2024: Biomedicines
https://read.qxmd.com/read/38533279/sglt2-inhibitors-paradigm-shift-from-diabetes-care-to-metabolic-care-an-indian-perspective
#9
REVIEW
K M Prasanna Kumar, A G Unnikrishnan, Pankaj Jariwala, Ashwani Mehta, Richa Chaturvedi, Sagar Panchal, Preet Lakhani, Rachana Acharya, Jitendra Dixit
The prevalence and burden of diabetes are on the rise in India, making it 'the diabetes capital of the world'. Comorbidities such as obesity, cardiovascular (CV) complications, chronic kidney disease (CKD), non-alcoholic fatty liver disease (NAFLD), and neurodegenerative diseases are common in patients with diabetes. Recent breakthroughs in diabetes medications and continuous glucose monitoring have resulted in a paradigm shift in diabetes care. Hence, a review in the Indian context is warranted. This review focuses on the existing evidence (gathered by a systematic literature search utilising online databases such as PubMed) on the metabolic, cardio-renoprotective, and hepatoprotective effects of sodium-glucose co-transporter 2 (SGLT2) inhibition, particularly in the Indian setting...
2024: Indian Journal of Endocrinology and Metabolism
https://read.qxmd.com/read/38532020/contemporary-pharmacological-treatment-and-management-of-heart-failure
#10
REVIEW
Biykem Bozkurt
The prevention and treatment strategies for heart failure (HF) have evolved in the past two decades. The stages of HF have been redefined, with recognition of the pre-HF state, which encompasses asymptomatic patients who have developed either structural or functional cardiac abnormalities or have elevated plasma levels of natriuretic peptides or cardiac troponin. The first-line treatment of patients with HF with reduced ejection fraction includes foundational therapies with angiotensin receptor-neprilysin inhibitors, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, β-blockers, mineralocorticoid receptor antagonists, sodium-glucose cotransporter 2 (SGLT2) inhibitors and diuretics...
March 26, 2024: Nature Reviews. Cardiology
https://read.qxmd.com/read/38530620/sodium-glucose-cotransporter-2-inhibitors-and-cancer-a-systematic-review-and-meta-analysis
#11
JOURNAL ARTICLE
B Xu, B Kang, S Li, S Fan, J Zhou
BACKGROUND: The effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on cancer has yet to be fully elucidated. OBJECTIVE: This systematic review and meta-analysis investigated the effects of SGLT2 inhibitors on cancer. METHODS: We searched the PubMed and ClinicalTrials.gov databases up to July 15, 2023, to identify eligible randomized, double-blind, placebo-controlled trials that lasted at least ≥24 weeks. The primary outcome was the overall cancer incidence, and the secondary outcomes were the incidences of various types of cancer...
March 26, 2024: Journal of Endocrinological Investigation
https://read.qxmd.com/read/38528820/comparison-of-estimated-glomerular-filtration-rate-change-with-sodium-glucose-cotransporter-2-inhibitors-versus-glucagon-like-peptide-1-receptor-agonists-among-people-with-diabetes-a-propensity-score-matching-study
#12
JOURNAL ARTICLE
Yuta Suzuki, Hidehiro Kaneko, Hajime Nagasawa, Akira Okada, Katsuhito Fujiu, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Akira Nishiyama, Tomohito Gohda, Yusuke Suzuki, Koichi Node, Hideo Yasunaga, Masaomi Nangaku, Issei Komuro
AIM: To compare the risk of developing kidney outcomes with use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) versus use of sodium-glucose cotransporter-2 (SGLT2) inhibitors among individuals with diabetes. MATERIALS AND METHODS: In this retrospective observational study, we analysed 12 338 individuals with diabetes who newly initiated SGLT2 inhibitors or GLP-1RAs using data from the JMDC claims database. The primary outcome was change in the estimated glomerular filtration rate (eGFR), estimated using a linear mixed-effects model...
March 26, 2024: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/38527558/dapagliflozin-ameliorates-hepatic-steatosis-via-suppressing-lxr%C3%AE-mediated-synthesis-of-lipids-and-bile-acids
#13
JOURNAL ARTICLE
Zijie Jin, Ruotong Yin, Yan Yuan, Chen Zheng, Peng Zhang, Yalin Wang, Hongbo Weng
Nonalcoholic fatty liver disease (NAFLD) prevalence is rising globally with no pharmacotherapies approved. Hepatic steatosis is closely associated with progression and prognosis of NAFLD. Dapagliflozin, kind of sodium-glucose cotransporter 2 (SGLT2) inhibitor, was found to improve NAFLD in clinical trials, while the underlying mechanism remains poorly elucidated. Here, we reported that dapagliflozin effectively mitigated liver injury and relieved lipid metabolism disorders in vivo. Further investigation showed that dapagliflozin markedly suppressed Liver X Receptor α (LXRα)-mediated synthesis of de novo lipids and bile acids (BAs)...
March 23, 2024: Biochemical Pharmacology
https://read.qxmd.com/read/38525377/sglt2-inhibitors-beyond-glycemic-control
#14
JOURNAL ARTICLE
Irtiza Hasan, Tasnuva Rashid, Vishal Jaikaransingh, Charles Heilig, Emaad M Abdel-Rahman, Alaa S Awad
Multiple randomized controlled trials have extensively examined the therapeutic effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors, ushering in a transformative approach to treating individuals with type 2 diabetes mellitus (DM). Notably, emerging reports have drawn attention to the potential positive impacts of SGLT2 inhibitors in nondiabetic patients. In an effort to delve into this phenomenon, a comprehensive systematic literature review spanning PubMed (NLM), Medline (Ovid), and Cochrane Library, covering publications from 2000 to 2024 was undertaken...
March 2024: Journal of Clinical & Translational Endocrinology
https://read.qxmd.com/read/38523292/sglt2-inhibition-and-three-urological-cancers-up-to-date-results
#15
JOURNAL ARTICLE
Lede Lin, Kang Ning, Liyuan Xiang, Liao Peng, Xiang Li
OBJECTIVE: To identify the causal role of sodium-glucose cotransporter 2 (SGLT2) inhibition on three urological cancers. METHODS: Six single nucleotide polymorphisms associated with the expression level of SLC5A2, a proxy for SGLT2 inhibition, from a recent publication were extracted. Three common urological cancers, including bladder cancer, prostate cancer and kidney cancer, were analysed. The main cohort of bladder cancer was derived from UK Biobank (1279 cases and 372,016 controls)...
March 2024: Diabetes/metabolism Research and Reviews
https://read.qxmd.com/read/38523127/sglt2-inhibitors-and-kidney-protection-mechanisms-beyond-tubulo-glomerular-feedback
#16
JOURNAL ARTICLE
Ashish Upadhyay
Sodium-glucose cotransporter 2 (SGLT2)-inhibitors reduce the risk for kidney failure and are a key component of guideline-directed therapy for chronic kidney disease. While SGLT2-inhibitors' ability to activate tubulo-glomerular feedback and reduce hyperfiltration-mediated kidney injury is considered to be the central mechanism for kidney protection, recent data from experimental studies raises questions on the primacy of this mechanism. This review examines SGLT2-inhibitors' role in tubulo-glomerular feedback and summarizes emerging evidence on following of SGLT2-inhibitors' other putative mechanisms for kidney protection: optimization of kidney's energy substrate utilization and delivery, regulation of autophagy and maintenance of cellular homeostasis, attenuation of sympathetic hyperactivity, and improvement in vascular health and microvascular function...
March 25, 2024: Kidney360
https://read.qxmd.com/read/38521442/dual-sglt1-and-sglt2-inhibition-more-than-the-sum-of-its-parts
#17
JOURNAL ARTICLE
Enrique Sánchez-Muñoz, Juan Antonio Requena-Ibáñez, Juan José Badimón
No abstract text is available yet for this article.
March 21, 2024: Revista Española de Cardiología
https://read.qxmd.com/read/38520170/a-comparison-of-sodium-glucose-co-transporter-2-inhibitor-kidney-outcome-trial-participants-with-a-real-world-chronic-kidney-disease-primary-care-population
#18
JOURNAL ARTICLE
Anna K Forbes, William Hinton, Michael D Feher, William Elson, José M Ordóñez-Mena, Mark Joy, Xuejuan Fan, Debasish Banerjee, Nicholas I Cole, Neil Munro, Martin Whyte, Rebecca J Suckling, Pauline A Swift, Simon de Lusignan
BACKGROUND/HYPOTHESIS: Observational studies suggest sodium-glucose co-transporter-2 (SGLT2) inhibitor kidney outcome trials are not representative of the broader population of people with chronic kidney disease (CKD). However, there are limited data on the generalisability to those without co-existing type 2 diabetes (T2D), and the representativeness of the EMPA-KIDNEY trial has not been adequately explored. We hypothesised that SGLT2 inhibitor kidney outcome trials are more representative of people with co-existing T2D than those without, and that EMPA-KIDNEY is more representative than previous trials...
March 22, 2024: Nephrology, Dialysis, Transplantation
https://read.qxmd.com/read/38520149/sodium-glucose-cotransporter-2-inhibitors-and-the-risk-of-atrial-fibrillation-in-patients-with-type-2-diabetes-a-population-based-cohort-study
#19
JOURNAL ARTICLE
Talip E Eroglu, Ruben Coronel, Patrick C Souverein
AIMS: Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) have a direct cardiac effect that is likely to be independent of its glucose lowering renal effect. Previous research has shown that SGLT2-is mitigate heart failure and prevent arrhythmic cardiac death. Our objective is to determine whether SGLT-2is reduce atrial fibrillation (AF) in comparison to other second-to third-line antidiabetic drugs in type 2 diabetes. METHODS AND RESULTS: We conducted a population-based, new-user active comparator cohort study using data from the UK Clinical Practice Research Datalink...
March 22, 2024: European Heart Journal. Cardiovascular Pharmacotherapy
https://read.qxmd.com/read/38517337/sodium-glucose-cotransporter-2-inhibitors-are-they-ready-for-prime-time-in-the-management-of-lupus-nephritis
#20
JOURNAL ARTICLE
Benjamin R Wagner, Panduranga S Rao
PURPOSE OF REVIEW: Lupus nephritis is a common complication of systemic lupus erythematosus and is associated with significant morbidity and mortality. The utility of sodium-glucose cotransporter 2 (SGLT2) inhibitors in the management of lupus nephritis is currently uncertain. Here, we summarize the rationale for their use among patient with lupus nephritis. RECENT FINDINGS: SGLT2 inhibitors were initially developed as antihyperglycemic agents. They have since been shown to have additional, profound effects to slow the progression of chronic kidney disease and lessen the long-term risks of cardiovascular disease in large clinic trials of patients with chronic kidney disease, with and without diabetes, as well as in patients with and without proteinuria...
May 1, 2024: Current Opinion in Rheumatology
keyword
keyword
9542
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.